NASDAQ:VTGN

VistaGen Therapeutics Stock Forecast, Price & News

$2.08
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.01
Now: $2.08
$2.11
50-Day Range
$2.04
MA: $2.25
$2.55
52-Week Range
$0.35
Now: $2.08
$3.18
Volume1.18 million shs
Average Volume3.47 million shs
Market Capitalization$298.15 million
P/E RatioN/A
Dividend YieldN/A
Beta0.52
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.
VistaGen Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VTGN
CUSIPN/A
Phone650-577-3600
Employees11
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.12) per share

Profitability

Net Income$-20,770,000.00

Miscellaneous

Market Cap$298.15 million
Next Earnings Date7/5/2021 (Estimated)
OptionableNot Optionable

Headlines

Will SAD Trial Make VistaGen Investors Happy?
February 19, 2021 |  nasdaq.com
Why VistaGen Therapeutics Stock Is Soaring Today
February 18, 2021 |  finance.yahoo.com
VISTAGEN THERAPEUTIC (VSTA) Q3 2020 Earnings Call Transcript
November 19, 2020 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.28 out of 5 stars

Medical Sector

832nd out of 2,019 stocks

Pharmaceutical Preparations Industry

400th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$2.08
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











VistaGen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

Is VistaGen Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VistaGen Therapeutics stock.
View analyst ratings for VistaGen Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than VistaGen Therapeutics?

Wall Street analysts have given VistaGen Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but VistaGen Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting VistaGen Therapeutics?

VistaGen Therapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 6,230,000 shares, a decrease of 32.5% from the March 15th total of 9,230,000 shares. Based on an average daily trading volume, of 3,410,000 shares, the short-interest ratio is currently 1.8 days.
View VistaGen Therapeutics' Short Interest
.

When is VistaGen Therapeutics' next earnings date?

VistaGen Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, July 5th 2021.
View our earnings forecast for VistaGen Therapeutics
.

How were VistaGen Therapeutics' earnings last quarter?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) released its quarterly earnings results on Thursday, February, 11th. The company reported ($0.07) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.02. The firm had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.33 million.
View VistaGen Therapeutics' earnings history
.

How has VistaGen Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

VistaGen Therapeutics' stock was trading at $0.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VTGN stock has increased by 316.0% and is now trading at $2.08.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for VTGN?

4 brokerages have issued 12-month price objectives for VistaGen Therapeutics' stock. Their forecasts range from $5.00 to $6.00. On average, they expect VistaGen Therapeutics' share price to reach $5.67 in the next twelve months. This suggests a possible upside of 172.4% from the stock's current price.
View analysts' price targets for VistaGen Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are VistaGen Therapeutics' key executives?

VistaGen Therapeutics' management team includes the following people:
  • Mr. Shawn K. Singh, CEO & Director (Age 58, Pay $498k)
  • Dr. H. Ralph Snodgrass, Founder, Pres, Chief Scientific Officer & Director (Age 71, Pay $416.85k)
  • Mr. Jerrold D. Dotson CPA, CFO, VP & Sec. (Age 68, Pay $367.5k)
  • Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 55, Pay $300k)
  • Dr. Mark A. Smith, Chief Medical Officer (Age 66, Pay $416.85k)
  • Dr. Mark J. Ginski, Sr. VP and Head of Chemistry, Manufacturing & Controls (Age 49)

Who are some of VistaGen Therapeutics' key competitors?

What other stocks do shareholders of VistaGen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

What is VistaGen Therapeutics' stock symbol?

VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

Who are VistaGen Therapeutics' major shareholders?

VistaGen Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Chesley Taft & Associates LLC (0.01%).
View institutional ownership trends for VistaGen Therapeutics
.

Which institutional investors are buying VistaGen Therapeutics stock?

VTGN stock was acquired by a variety of institutional investors in the last quarter, including Chesley Taft & Associates LLC.
View insider buying and selling activity for VistaGen Therapeutics
or or view top insider-buying stocks.

How do I buy shares of VistaGen Therapeutics?

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VistaGen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $2.08.

How much money does VistaGen Therapeutics make?

VistaGen Therapeutics has a market capitalization of $298.15 million. The company earns $-20,770,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How many employees does VistaGen Therapeutics have?

VistaGen Therapeutics employs 11 workers across the globe.

What is VistaGen Therapeutics' official website?

The official website for VistaGen Therapeutics is www.vistagen.com.

Where are VistaGen Therapeutics' headquarters?

VistaGen Therapeutics is headquartered at 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact VistaGen Therapeutics?

VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected]


This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.